References
- Rogers YH, Venter JC. Genomics: massively parallel sequencing. Nature437(7057), 326–327 (2005).
- McGuire AL, Gibbs RA. Genetics. No longer de-identified. Science312(5772), 370–371 (2006).
- Kaye J, Boddington P, de Vries J et al. Ethical implications of the use of whole genome methods in medical research. Eur. J. Hum. Genet.18(4), 398–403 (2010).
- Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: a review of statistical methods and recommendations for their application. Am. J. Hum. Genet.86, 6–22 (2010).
- Diamandis EP. Next-generation sequencing: a new revolution in molecular diagnostics?. Clin. Chem.55(12), 2088–2092 (2009).
- Malin BA. An evaluation of the current state of genomic data privacy protection technology and a roadmap for the future. J. Am. Med. Inform. Assoc.12, 28–34 (2005).
- Sweeney L. Weaving technology and policy together to maintain confidentiality. J. Law Med. Ethics25(2–3), 98–110 (1997).
- Wylie JE, Mineau GP. Biomedical databases: protecting privacy and promoting research. Trends Biotechnol.21(3), 113–116 (2003).
- Lin Z, Owen AB, Altman RB. Genetics. Genomic research and human subject privacy. Science305, 183 (2004).
- ten Bosch JR, Grody WW. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J. Mol. Diagn.10(6), 484–492 (2008).
- Easton DF, Deffenbaugh AM, Pruss D et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet.81(5), 873–883 (2007).
- Grody WW. Ethical issues raised by genetic testing with oligonucleotide microarrays. Mol. Biotechnol.23(2), 127–138 (2003).
- Maddalena A, Bale S, Das S et al. Technical standards and guidelines: molecular genetic testing for ultra-rare disorders. Genet. Med.7(8), 571–583 (2005).
- Grody WW, Richards CS. New quality assurance standards for rare disease testing. Genet. Med.10(5), 320–324 (2008).